StockNews.AI
TLX
StockNews.AI
209 days

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

1. Telix Pharmaceuticals acquires ImaginAb's therapeutic pipeline and technology platform. 2. Deal enhances Telix's capability in new disease areas with advanced radiotherapeutics. 3. ImaginAb will focus on CD8 ImmunoPET, currently in Phase 2 clinical trials. 4. This transaction validates ImaginAb's innovative minibody platform in oncology.

M&A
-4.53%Current Return
VS
+0.36%S&P 500
$17.942801/22 01:47 PM EDTEvent Start
$17.1301/23 08:09 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

The acquisition broadens Telix's product offerings and future market potential, similar to other biotech acquisitions boosting stock prices.

How important is it?

This M&A strengthens Telix’s position and capabilities, making it a significant development.

Why Long Term?

The integration might take time to reflect benefits in TLX, similar to historical biotech consolidations.

Related Companies

TLX
, /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL). Following the closing of this transaction, ImaginAb Inc., will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology. In addition, ImaginAb will continue to partner in advancing the pivotal prostate cancer imaging agent, which is currently being evaluated in Phase 2 clinical trials and as a surgical resection tool.   Dr. Anna Wu, Founder of ImaginAb, commented, "We are very pleased that Telix recognizes the potential of our novel biological technology platform including enabling Telix to explore new disease areas with state-of-the-art radiotherapeutic technology. These radiopharmaceutical agents represent the culmination of significant effort and resources by our scientific team.  I extend my congratulations to everyone at ImaginAb for reaching this significant milestone. This transaction further validates our novel minibody platform." Dr. Wu continued, "With the sale of our radiopharmaceutical platform, ImaginAb will continue the development of its CD8 platform.  We are encouraged that numerous pharmaceutical and biotech companies have incorporated our technology in their immuno-oncology clinical trials." Jefferies LLC and Stifel, Nicolaus & Company, Incorporated served as financial advisors to ImaginAb on the transaction. About ImaginAb, Inc. ImaginAb, Inc. is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies that maintain the specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available positron emission tomography (PET) and optical imaging technology, these novel targeting agents are able to bind specifically to cell surface targets. The company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb's pipeline and technology, visit www.imaginab.com. About CD8 ImmunoPET The 89Zr CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) is a [89Zr]-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8+ cells in patients. CD8+ cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8+ cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes. About Optical PSMA The Optical PSMA Imaging Agent  (IR-800 IAB2 Minibody) is a fluorescent labelled minibody that binds the PSMA  receptor present on cancer cells including prostate cancer and is used for quantitative, non-invasive PET imaging of PSMA+ cells in patients undergoing surgery to remove cancerous tissue . As such, imaging of PSMA + cells  may be used to guide clinicians during surgery to identify cancerous tissue and aid tissue resection. SOURCE ImaginAb, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News